UnitedHealth Group (UNH)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
$428.28+2.46%
Close 2026-07-07 · 1-day change
Reading UNH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track UNH free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
Reading UNH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track UNH free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 10% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 20%.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 17% growth a year, above the roughly 1% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskUnitedHealth Group's growth relies on its strong revenue outlook and recent earnings performance. Revenue is projected between $445.5 billion and $448.0 billion for 2025. It trades at 26× P/E, slightly below the peer median of 26.2×. The market is pricing in more growth than expected, indicating full expectations. A specific risk is the 12% probability of missing next-quarter earnings. Peer multiples imply a price about 17% below where it trades. This read is provisional.
Trailing returns as of 2026-07-07. UNH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering UNH (as of Jul 2026).
Based on 11 Wall Street analysts offering 12-month price targets for UNH in the last 4 months.
A consensus fair price across 12 valuation methods, at three horizons. Current price $428.28. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Managed Health Care — fair value, gap to price, and forward P/E.
Positive insights on UnitedHealth's performance support growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $428.28
The last 12 months of price, then the range of analyst 12-month targets from today’s $428.28.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Raise 2026 EPS outlook to >$17.35
AI investment supports growth and EPS outlook.
Advances: Raise 2026 EPS outlook to >$17.35
AI cost-cutting supports EPS growth objectives.
Advances: 2025 revenue outlook $445.5B-$448.0B
Positive outlook on Optum supports revenue growth.
Leadership uncertainty could impact strategic execution.
CEO's legal issues could impact company leadership and stability.
CEO's legal issues could impact company leadership and stability.
CEO's legal issues could impact company leadership and stability.